IL6 and irritable bowel syndrome: Additionally, some studies have indicated that MBIs likely represented a promising intervention to reduce inflammation in IBD patients because MBIs could effectively decrease the levels of mucosal inflammatory biomarkers, including IL-6, fecal calprotectin, and CRP levels (194, 196, 198).